NellOne Therapeutics

NellOne Therapeutics, Inc. is a regenerative medicine company based in Oak Ridge, Tennessee, focused on developing and commercializing protein therapeutics aimed at restoring cardiac muscle mass and function in patients recovering from myocardial infarction and congestive heart failure. The company was established in 2007 as a spin-out from the U.S. Department of Energy's Oak Ridge National Laboratory, where research led by Dr. Cymbeline Culiat identified the Nell1 gene's role in the formation of essential mammalian tissues and organs. NellOne is dedicated to translating these scientific discoveries into clinical applications, specifically by leveraging Nell1 protein therapeutics to rebuild cardiac muscle and improve patient outcomes following heart-related conditions.